- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Transplantation & Cellular Therapy Meetings | Conferences
Interim Data Targeting CD117 Show Promising MRD Results and Safety in MDS/AML
April 27, 2022
JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
April 25, 2022
Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
Certain Baseline Disease Features are Prognostic of CR/sCR in Multiple Myeloma
April 25, 2022
Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.
Topical Ruxolitinib Shows Early Efficacy and Safety for Cutaneous cGVHD
April 25, 2022
Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.
Axi-Cel Continues to Show Duration of Response and Efficacy in iNHL After 2-Year Follow-Up
April 25, 2022
Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.
Lisocabtagene Maraleucel Achieves Durable Response in R/R Large B-Cell Lymphoma
April 24, 2022
In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.
Belimumab May Be a Prophylaxis Option for cGVHD After Allogenic Transplant
April 24, 2022
The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.
Less GVHD and Prednisone Use With Abatacept Seen Post SCT
April 24, 2022
In a phase 2 trial, rates of steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant were reduced.
Responses to Topical Ruxolitinib in Patients With cGVHD Reveals Novel Gene Signature
April 24, 2022
In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.
Long-Term OS Data for Axi-Cel Hint Short-Term EFS is a Surrogate End Point for R/R LBCL
April 24, 2022
According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.